Understanding 2019 CDC Recommendations for Pneumococcal Disease in Adults Ages 65+

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding 2019 CDC Recommendations for Pneumococcal Disease in Adults Ages 65+

Program Information

Program Information

Understanding 2019 CDC Recommendations for Pneumococcal Disease in Adults Ages 65+

Catch up on the 2019 recommendations from the CDC on pneumococcal disease in adults ages 65 years and older.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    Prescribing Information | Patient Information

    In November 2019, the CDC updated their pneumococcal disease recommendations for adults ages 65+. Here to discuss the updated recommendations for this age group as well as why they have changed is Dr. Javeed Siddiqui, Chief Medical Officer at TeleMed2U.

  • Indications and Select Safety Information

    Indications and Usage 

    PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

    PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

    PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

    Select Safety Information for PNEUMOVAX 23

    Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

    Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

    Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

    Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

    Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

    PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

    The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

    For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

    Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

    Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

Programs 4/13/21